Document is current
Any future updates will be listed below
-
Authors
Gross, Mitchell E. https://orcid.org/0000-0002-1691-921X
Agus, David B. https://orcid.org/0000-0002-7499-7822
Dorff, Tanya B.
Pinski, Jacek K.
Quinn, David I.
Castellanos, Olga https://orcid.org/0000-0002-2883-8310
Gilmore, Patrick
Shih, Jean C.
- License Information
-
More Information
Article History
Received: 4 October 2019
Revised: 30 January 2020
Accepted: 7 February 2020
First Online: 3 March 2020
Compliance with ethical standards
:
: The clinical research protocol was approved by the Institutional Review Board (IRB) at the University of Southern California (USC), Los Angeles, California. All patients gave prospective consent to participate in all study procedures.
: MEG serves as a consultant for Amgen and BeiGene and receives institutional research funding from Clovis Oncology, Glaxo-Smith-Kline, and BeiGene. TBD serves as a consultant for Bayer, Noxopharm, Roche, and Seattle Genetics, is a speaker for Exelixis, and receives institutional research funding from Bayer. DIQ serves as a consultant for Astellas, AstraZeneca, Bayer, Genzyme-Sanofi, Jannsen, Clovis and Pfizer. JCS has a patent entitled Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer. US Patent No. 9.771,625. The other authors declare no conflicts of interest.
